Publications by authors named "E Murena"
Unlabelled: Hemoglobin (Hb) levels have emerged as a useful tool for risk stratification and the prediction of outcome after myocardial infarction. We aimed at evaluating the prognostic impact of this parameter among patients in advanced age, where the larger prevalence of anemia and the higher rate of comorbidities could directly impact on the cardiovascular risk.
Methods: All the patients in the ELDERLY-2 trial, were included in this analysis and stratified according to the values of hemoglobin at admission.
Background: Worse outcomes have been reported for women, compared with men, after an acute coronary syndrome (ACS). Whether this difference persists in elderly patients undergoing similar invasive treatment has not been studied. We investigated sex-related differences in 1-year outcome of elderly acute coronary syndrome patients treated by percutaneous coronary intervention (PCI).
View Article and Find Full Text PDFImpact of renal dysfunction and acute kidney injury on outcome in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Eur Heart J Acute Cardiovasc Care
December 2021
Article Synopsis
- * Out of 1,904 patients studied, a significant portion (57% moderate, 11% severe renal dysfunction) showed higher rates of overall and cardiovascular mortality at the 12-month mark compared to those with no or mild dysfunction.
- * The findings suggest that severe renal dysfunction significantly increases the risk of adverse outcomes, highlighting the need for targeted treatment strategies in this high-risk population.
Background: Despite recent improvements in percutaneous coronary revascularization and antithrombotic therapies for the treatment of acute coronary syndromes, the outcome is still unsatisfactory in high-risk patients, such as the elderly and patients with diabetes. The aim of the current study was to investigate the prognostic impact of diabetes on clinical outcome among patients included in the Elderly-ACS 2 trial, a randomized, open-label, blinded endpoint study carried out at 32 centers in Italy.
Methods: Our population is represented by 1443 patients included in the Elderly-ACS 2 trial.